PL3386527T3 - Kompozycje do zastosowania w leczeniu lub łagodzeniu neurozapalenia, neurodegeneracji, bólu neuropatycznego i migreny - Google Patents

Kompozycje do zastosowania w leczeniu lub łagodzeniu neurozapalenia, neurodegeneracji, bólu neuropatycznego i migreny

Info

Publication number
PL3386527T3
PL3386527T3 PL16873645T PL16873645T PL3386527T3 PL 3386527 T3 PL3386527 T3 PL 3386527T3 PL 16873645 T PL16873645 T PL 16873645T PL 16873645 T PL16873645 T PL 16873645T PL 3386527 T3 PL3386527 T3 PL 3386527T3
Authority
PL
Poland
Prior art keywords
neurodegeneration
migraine
compositions
treating
neuropathic pain
Prior art date
Application number
PL16873645T
Other languages
English (en)
Inventor
Yury Miller
Tony L. Yaksh
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of PL3386527T3 publication Critical patent/PL3386527T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/52—Isomerases (5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y501/00—Racemaces and epimerases (5.1)
    • C12Y501/99—Racemaces and epimerases (5.1) acting on other compounds (5.1.99)
    • C12Y501/99006—NAD(P)H-hydrate epimerase (5.1.99.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL16873645T 2015-12-10 2016-12-05 Kompozycje do zastosowania w leczeniu lub łagodzeniu neurozapalenia, neurodegeneracji, bólu neuropatycznego i migreny PL3386527T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562265752P 2015-12-10 2015-12-10
PCT/US2016/064938 WO2017100125A1 (en) 2015-12-10 2016-12-05 Compositions and methods for treating or ameliorating neuroinflammation, neurodegeneration, neuropathic pain, and migraine
EP16873645.2A EP3386527B1 (en) 2015-12-10 2016-12-05 Compositions for use in treating or ameliorating neuroinflammation, neurodegeneration, neuropathic pain, and migraine

Publications (1)

Publication Number Publication Date
PL3386527T3 true PL3386527T3 (pl) 2022-01-31

Family

ID=59013143

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16873645T PL3386527T3 (pl) 2015-12-10 2016-12-05 Kompozycje do zastosowania w leczeniu lub łagodzeniu neurozapalenia, neurodegeneracji, bólu neuropatycznego i migreny

Country Status (8)

Country Link
US (2) US10729788B2 (pl)
EP (1) EP3386527B1 (pl)
DK (1) DK3386527T3 (pl)
ES (1) ES2883417T3 (pl)
HU (1) HUE055326T2 (pl)
PL (1) PL3386527T3 (pl)
PT (1) PT3386527T (pl)
WO (1) WO2017100125A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200144576A (ko) * 2018-05-17 2020-12-29 주식회사 헬릭스미스 화학요법-유발 말초신경병증과 관련된 신경병증성 통증의 치료
WO2021240488A1 (en) * 2020-05-27 2021-12-02 Baylor College Of Medicine Compositions and methods for treating neovascularization and ischemic retinopathies by targeting angiogenesis and cholesterol transport
WO2022081245A1 (en) * 2020-10-13 2022-04-21 The Methodist Hospital System Compositions and methods for increasing lymphangiogenesis
AU2022238450A1 (en) * 2021-03-18 2023-11-02 The Regents Of The University Of California Compositions and methods for targeting inflammatory or activated cells and treating or ameliorating inflammatory conditions and pain
WO2025076208A1 (en) * 2023-10-03 2025-04-10 Raft Pharmaceuticals, Inc. Compositions and methods for treating pain disorders

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8513702D0 (en) 1985-05-30 1985-07-03 Gill S S Expansible trocar
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US5874268A (en) 1996-09-23 1999-02-23 Duke University Method of introducing exogenous compounds into cells by electroporation and apparatus for same
SE9704076D0 (sv) 1997-11-06 1997-11-06 Holdingbolaget Vid Goeteborgs Method for permeabilisation of cell structures and use thereof
US6589503B1 (en) 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US7343205B1 (en) 2002-08-20 2008-03-11 Boston Scientific Neuromodulation Corp. System and method for insertion of a device into the brain
EP1551292B1 (en) 2002-09-24 2016-04-27 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Imaging method for convection enhanced delivery of therapeutic agents
US20050142141A1 (en) 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
US20040151766A1 (en) 2003-01-30 2004-08-05 Monahan Sean D. Protein and peptide delivery to mammalian cells in vitro
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US20050136121A1 (en) 2003-12-22 2005-06-23 Shear/Kershman Laboratories, Inc. Oral peptide delivery system with improved bioavailability
CA2549966A1 (en) 2003-12-24 2005-07-07 Ltt Bio-Pharma Co., Ltd. Drug-containing nanoparticle, process for producing the same and parenterally administered preparation from the nanoparticle
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
EP1773298A1 (en) 2004-08-06 2007-04-18 Biospectrum, Inc. Multiple layered liposome and preparation method thereof
EP1812074B1 (en) 2004-10-18 2010-12-29 Nitto Denko Corporation Intracellular peptide delivery
US20060129126A1 (en) 2004-11-19 2006-06-15 Kaplitt Michael G Infusion device and method for infusing material into the brain of a patient
AU2006274413B2 (en) 2005-07-27 2013-01-10 Arbutus Biopharma Corporation Systems and methods for manufacturing liposomes
CN100357325C (zh) 2005-10-23 2007-12-26 王贤理 一种抗apoA I、apoB抗体制备方法以及用于检测apoA I、apoB的试剂盒
WO2008067183A1 (en) 2006-11-30 2008-06-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education A device for cell delivery into the brain or body
US8419710B2 (en) 2006-12-06 2013-04-16 Medtronic, Inc. Methods for infusing fluids via an implantable infusion system
WO2012019060A1 (en) 2010-08-05 2012-02-09 Joslin Diabetes Center, Inc. Predicting and treating diabetic complications
WO2012078618A2 (en) 2010-12-07 2012-06-14 Joslin Diabetes Center, Inc. Predicting and treating diabetic complications
US10364275B2 (en) 2013-05-27 2019-07-30 The Regents Of The University Of California Methods for treating inflammatory responses or diseases caused by inflammation using ApoA-I binding protein (APOA1BP)

Also Published As

Publication number Publication date
EP3386527A4 (en) 2019-07-03
EP3386527B1 (en) 2021-05-26
US20200390906A1 (en) 2020-12-17
US20180360993A1 (en) 2018-12-20
ES2883417T3 (es) 2021-12-07
EP3386527A1 (en) 2018-10-17
HUE055326T2 (hu) 2021-11-29
WO2017100125A1 (en) 2017-06-15
US10729788B2 (en) 2020-08-04
DK3386527T3 (da) 2021-08-23
PT3386527T (pt) 2021-09-27
US11478556B2 (en) 2022-10-25

Similar Documents

Publication Publication Date Title
IL304820A (en) Preparations and methods for the treatment of cancer
IL269620A (en) Preparations and methods for the treatment of phenylketonuria
ZA201706798B (en) Hair treatment compositions
IL269637A (en) Preparations and methods for the treatment of synovial diseases
IL256523A (en) Compositions and methods for treating cancer
EP3226972A4 (en) Methods and compositions for treating migraine and conditions associated with pain
IL255638A (en) Compositions and methods for treating cancer
PL3386527T3 (pl) Kompozycje do zastosowania w leczeniu lub łagodzeniu neurozapalenia, neurodegeneracji, bólu neuropatycznego i migreny
ZA201802376B (en) Compositions and methods for treatment of homocystinuria
IL271758A (en) Statin preparations and methods for use in the treatment of synuclein pathologies
GB2581876B (en) Compositions for use in the treatment of endometrial disorder
IL251881A0 (en) Preparations for the treatment of acute, post-operative or chronic pain and methods of using them
IL271923A (en) Methods and compositions for treating addictions
SG11201802292UA (en) Composition for treating pain
IL274822A (en) Substances for the treatment of depression and migraine
IL272945A (en) Local preparations and methods of treatment
IL271211B1 (en) Acetyl leucine for use in the treatment of migraine
ZA201802268B (en) Methods and compositions for preventing or treating cancer
IL256763A (en) Compositions and methods for treating cancer
GB201513543D0 (en) Compositions for use in the treatment of diabetes
GB2560769B (en) Compounds and compositions for use in treating psoriasis
PL2845589T3 (pl) Kompozycja do zapobiegania i leczenia migreny lub bólu neuropatycznego
GB201521083D0 (en) Compositions for treatment and methods thereof
GB201508518D0 (en) Hair treatment compositions and methods
GB201511447D0 (en) Compositions and methods for treating biofilms